Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Case Western Reserve University Receives $5M for the Center for Stem Cell and Regenerative Medicine

Published: Tuesday, July 14, 2009
Last Updated: Tuesday, July 14, 2009
Bookmark and Share
The funding will help support new stem cell technologies including two commercial, four emerging and three pilot projects.

The Center for Stem Cell & Regenerative Medicine (CSCRM), comprised of Case Western Reserve University, Cleveland Clinic (CC), University Hospitals (UH), and Athersys, Inc. has received $5 million from Ohio's Third Frontier Commission under the Research Commercialization Program.

The funding will help support new stem cell technologies including two commercial, four emerging and three pilot projects. This funding will be matched by each of the projects to create a $10 million grant benefiting stem cell and regenerative medicine in Ohio.

"This funding provides CSCRM the support it needs to continue to aggressively move new technologies from academic labs towards commercial development," said Stan Gerson, director of the Center for Stem Cell & Regenerative Medicine. "We have linked corporate partners to our major projects and have been gratified by the development of a stem cell biotechnology commercial landscape in our region. Our goal is to rapidly move stem cell research from the lab to patients through clinical trials, using our strong background in preclinical models."

The continued research efforts will result in efficient clinical applications and commercialization of stem cells to benefit patients throughout Ohio. To date, such efforts have brought in $170 million in new commercial development and investment in Ohio.

"This grant continues to build distinctive and broad reach capabilities that are making Ohio a leader in the development and clinical use of cellular therapies," said Baiju R. Shah, President and CEO of BioEnterprise. "Ohioans benefit both through the resulting company development and jobs as well as by having access to leading-edge clinical therapies at our region's clinical institutions."

The use of stem cells has focused on leukemia and myeloma treatments with recent applications in cardiovascular disease. Current healthcare is limited to the use of drugs or devices to treat disease and injury. CSCRM, located in Northeast Ohio but collaborating state wide, is positioned to implement new stem cell technologies in the commercial and therapeutic arenas.

"I can see stem cells replacing drugs to improve many diseases," said Gerson. "Stem cells can replace injured cells, improve the function of many organs in the body and provide specific new functions to treat many diseases."

The Third Frontier funding will support the following commercial, emerging and pilot programs:

• Commercial programs:

The commercial projects are expected to generate significant near term value for the sponsoring companies and the State of Ohio.

Athersys and Kenneth Cooke (UHCMC and Case Western Reserve) will further evaluate MultiStem® to cure immunological reactions to cell related therapies for cancer. The goal of this project is to advance the commercialization of MultiStem® cell therapy by running a FDA approved Phase II clinical trial to evaluate the performance of the cells.

Juventas Therapeutics, spin out company from Marc Penn (CC), will develop its lead drug product, stromal cell derived factor 1 (SDF-1), through a Phase I clinical trial for critical limb ischemia.

• Emerging programs:

With further refinement of already established proof of concept, the following programs could mature into significant opportunities for CSCRM and the region.

Gerson is partnering with Lentigen, Inc, of Gaithersburg, Md., to develop a gene therapy approach to treating brain tumors.

Jean Welter (Case Western Reserve) and Adam Lambert (Oakwood Laboratories) are teaming up to develop a combination product comprised of a drug and Oakwood's proprietary sustained release technology to treat arthritic disease.

Eben Alsberg (Case Western Reserve) and Orthopediatrics of Warsaw, Ind., will use microspheres tuned to release a specific amount of drug over a prolonged period of time to tell the patient's cells to create cartilage.

Bruce Trapp (CC) and Vertex Pharmaceuticals of Cambridge, Mass., have identified a cell in the adult human brain and will evaluate its potential to treat a variety of neurodegenerative diseases and spinal cord injury.

• Pilot programs:

The pilot projects represent early stage, cutting edge scientific projects that were developed in the Center. While these projects are at an early stage, they were selected based upon their significance to the field and their potential economic impact if successfully matured. Funding for the three projects will be accompanied by a subset of eight new pilot projects determined through review by CSCRM oversight committees.

Paul Tesar (Case Western Reserve), Horst von Recum (Case Western Reserve) and Jeremy Rich (CC) will establish a Pluripotent Stem Cell Facility within Case Western Reserve and CC which will be the first of its kind in the State of Ohio.

Cell Targeting will apply its cell "painting" technology to direct umbilical cord blood stem cells to specific locations in the body to increase cell dosage and improve engraftment.

Zhenghong Lee (UHCMC) and Jeremy Rich (CC) will collaborate to develop a method to non-invasively image cancer stem cells through the development of radiolabeled tracers.

The CSCRM Administration, led by Debra Grega and Michael Gilkey, is responsible for coordinating, accounting and reporting on all of these projects, continuing and creating education programs on stem cells and regenerative medicine for middle school through graduate level students, executing a biennial international stem cell conference (MSC 2009), interfacing and cultivating new commercial interactions, developing new research collaborations within the State as well as internationally, and representing the Center in scientific conferences and public events.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stem Cells Hold Keys to Body’s Plan
Case Western Reserve researchers have discovered landmarks within pluripotent stem cells that guide how they develop to serve different purposes within the body.
Monday, June 09, 2014
Scientific News
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!